FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies

FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment

Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases

Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)